Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor ...

Rising prevalence, aging populations, and therapeutic innovation are reshaping the landscape of multiple myeloma care and driving sustained market gr ...

Astute Analytica is excited to announce the release of a comprehensive market assessment report titled “ Global Multiple Myeloma Treatment Market: Trends, Industry Competition Analysis, Revenue, and ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating multiple myeloma.